Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent or Metastatic Platinum-refractory SCCHN
NCT03226756Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Unicancer. Primary endpoint: Incidence of high-grade adverse events of interest. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03226756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226756.